We sought to investigate the antifibrotic effects of an artificial microRNA (miRNA) targeting connective tissue growth factor (CTGF) using the ultrasound-targeted cationic liposome-bearing microbubble destruction gene delivery system. Cationic liposomes were conjugated with microbubbles using a biotin-avidin system. Plasmids carrying the most effective artificial miRNA sequences were delivered by ultrasound-targeted cationic liposome-bearing microbubble destruction gene delivery system to rats with hepatic fibrosis. The results show that this method of gene delivery effectively transported the plasmids to the rat liver. The artificial miRNA reduced hepatic fibrosis pathological alterations as well as the protein and mRNA expressions of CTGF and transforming growth factor b1. Furthermore, the CTGF gene silencing decreased the levels of type I collagen and a-smooth muscle actin (Po0.01). These data suggest that delivery of an artificial miRNA targeted against CTGF using ultrasound-targeted cationic liposome-bearing microbubble destruction may be an efficacious therapeutic method to ameliorate hepatic fibrosis.
INTRODUCTION
Hepatic fibrosis is a common pathological change in the chronic liver injury characterised by the accumulation of extracellular matrix (ECM). 1 Following liver injury, hepatic stellate cells (HSCs) become activated and transform into myofibroblast-like cells that express alpha-smooth muscle actin (a-SMA) and produce ECM. 2, 3 Transforming growth factor b1 (TGF-b1) has been considered one of the most potent fibrogenic mediators to fibrosis. 4 Because of its multiple actions, the complete blockage of TGF-b1 may have serious side effects. Connective tissue growth factor (CTGF) has received significant attention as a downstream effector of the TGF-b1 fibrogenic effect. 5, 6 CTGF not only can lead to the activation, proliferation and migration of primary HSCs, but can also promote the accumulation of ECM components and inhibit their degradation. 7 Disruption of CTGF expression has been shown to effectively suppress the activation of HSCs and the accumulation of ECM. 8 CTGF expression is low or absent in the normal liver tissue; however, its expression progressively increases in the fibrotic liver. CTGF expression is significantly correlated with the development of hepatic fibrosis. 9 Strategies to block CTGF by small interfering RNAs have achieved favourable anti-fibrotic effects for treating hepatic fibrosis. 10, 11 On the basis of recent studies, microRNAs (miRNAs) have gained significant attention for the treatment of hepatic fibrosis. 12, 13 Artificial miRNAs (amiRNAs) exploit the backbone of natural miRNAs to generate designed miRNAs that can efficiently silence the gene of interest.
14 This strategy has produced highly efficient and specific gene silencing for therapeutic applications. 15, 16 However, the challenge is to effectively deliver amiRNAs to the target organ.
Ultrasound-targeted microbubble destruction (UTMD) has emerged as a novel non-viral gene delivery technique because of its safety, high efficiency and local gene transfer. 17, 18 This method involves the attachment of genes to microbubbles, which are then injected and circulated through blood vessels and destroyed at the target site by ultrasound insonation. 19 The destruction increases capillary permeability and generates transient holes in the cell membrane and releases the payload, which is incorporated intracellularly. Microbubbles, which consist of a gas core and a stabilizing shell. The size of microbubbles is usually less than 10 mm. Nevertheless, the gene-loading capacity of the microbubbles remains a consideration. Fortunately, studies have shown that the loading capacity can be increased by attaching cationic liposomes to the lipid shell of microbubbles. 20, 21 In this study, we utilised novel cationic liposome-bearing microbubbles combined with ultrasound to transfect a plasmid-based amiRNA designed against CTGF mRNA, which showed high genesilencing efficacy in vitro, to determine whether this technique could efficiently suppress the expression of CTGF and exert antifibrogenic effects on hepatic fibrosis in vivo.
RESULTS
The effect of artificial miRNA targeted against CTGF on CTGF expression in vitro Western blotting showed that there was no obvious decline in CTGF protein expression in the scrambled amiRNA group (amiScramble), compared with the untreated HSC-T6 cells group (blank). Cells treated with four different artificial miRNAs targeted against CTGF showed varying degrees of inhibition, and CTGF-4 exerted the strongest effect. The same effects were observed on CTGF mRNA expression levels ( Figure 1 ). These data suggest that the CTGF-4 vector provided the most effective inhibition of CTGF expression in HSC-T6 cells. Thus, the CTGF-4 vector was selected for subsequent experiments.
The characterisation of cationic liposomes The average particle size and the zeta potential (z) was 120 nm and 50 Mv, respectively, for the biotinylated cationic liposomes and 200 nm and 20 Mv, respectively, for the DNA-loading liposomes. Similar size distributions of cationic liposomes were found in transmission electron microscope image shown in Figure 2a . The biotinylated cationic liposomes appeared as spherical or nearly spherical nanoparticles. 3b-[N-(N,N-dimethylaminoethane)-carbamoyl]-cholesterol (DC-Chol) is a charged lipid that gives the liposomes a positive charge that can efficiently combine with a negatively charged DNA plasmid. A gel retardation assay showed that the biotinylated cationic liposomes/DNA volume ratio required to completely retain DNA in the complex was 6:1 ( Figure 2b ).
Properties of cationic liposome-bearing microbubbles
The concentration and size distribution of microbubbles carrying DNA-loading liposomes were determined to be 1-5 Â 10 9 ml À 1 and 1-7 mm, respectively, which allowed them to circulated through the microvessels and capillaries. As shown in Figure 3a , the surface of microbubble carrying DNA-loading liposomes appeared rough and was surrounded by a number of DNAloading liposomes with red fluorescence. The cationic liposome-bearing microbubbles exhibited acoustic activity. Similar to previous observations of common microbubbles, 22 the echo of the liver was low without the presence of cationic liposome-bearing microbubbles. The echo intensity of the liver significantly increased after the injection of cationic liposome-bearing microbubbles. Furthermore, this effect was clearly abated after the cationic liposome-bearing microbubbles were destroyed by ultrasound (Figure 3b-d) .
Delivery of amiRNA to the rat liver by cationic liposome-bearing microbubbles combined with ultrasound To explore whether the amiRNA expression plasmid is delivered into the rat liver by ultrasound-targeted novel cationic liposomebearing microbubbles destruction (UTMD) in vivo, we transferred it, including emerald green fluorescent protein (EmGFP) gene, as a reporter for the tracking of amiRNA-mediated expression. No expression was observed in the kidney, lung or spleen (data not shown). Inhibition of hepatic fibrosis with artificial microRNA D Yang et al but the fluorescence intensity in the treated liver was enhanced following UTMD at multiple time points when compared with the untreated normal group (Po0.01). Fluorescence intensity reached a maximum at 4 days, still presented at 7 days and weakened at 10 days when compared with the 24 h post-transfection group. The efficient delivery of EmGFP-labelled plasmid suggested that the amiRNA could be delivered to the liver in vivo and this effect remained at least 7 days post-transfection.
The effects of CTGF amiRNA on hepatic fibrosis pathology The results of haematoxylin and eosin staining and picrosirius red staining are shown in Figure 5 . The control liver had a normal lobular architecture, and red collagen fibres were deposited only around the blood vessels. The untreated hepatic fibrosis model group and the amiScramble-treated model group exhibited pseudo-lobular formations and abundant mature collagen fibres. Only mild fibrosis and small collagen staining areas were observed in the model group treated with amiCTGF ( Figure 5a ). The collagen staining areas in the amiCTGF-treated model group were markedly lower than in the model group and the amiScrambletreated group (Po0.01) (Figure 5b ).
Immunohistochemical staining of CTGF, TGF-b1, type I collagen and a-SMA The results of the immunohistochemical detection of CTGF, TGF-b1, type I collagen and a-SMA in each experimental group are shown in Figure 6 . The expression of CTGF, TGF-b1, type I collagen and a-SMA was significantly increased in the model group and the amiScramble-treated group, compared with the normal control group (Po0.01). However, the staining of these proteins was markedly decreased in the group treated with amiCTGF, compared with the model and the amiScramble-treated groups (Po0.01).
The inhibitory effects of CTGF and TGF-b1 in the rat liver as determined by western blotting The expression levels of CTGF and TGF-b1 protein were very low in the normal control group. There was a dramatic increase in the levels of CTGF and TGF-b1 protein expression in the model and amiScramble-treated groups, compared with the normal control group (Po0.01). However, the expressions of these proteins were markedly decreased in the amiCTGF-treated group, compared with the model and the amiScramble-treated groups (Po0.01) (Figure 7a and b).
Quantitative real-time PCR analysis of CTGF and TGF-b1 mRNA expression in the rat liver The expression levels of CTGF and TGF-b1 mRNA were very low in the normal control group. The CTGF and TGF-b1 mRNA levels were significantly increased in the model and amiScramble-treated groups, compared with the normal control group (Po0.01). However, the mRNA levels were markedly decreased after amiCTGF treatment, compared with the model and amiScramble-treated groups (Po0.01) (Figure 7c ).
DISCUSSION
A major obstacle for amiRNAs in vivo is the development of an efficient delivery system into the target organ. Although viral vector systems are efficient, their safety and the difficulty of targeting specific sites limit their applications. 23 Plasmid delivery methods are safer, but their transfection efficiencies are low. The use of hydrodynamic injections to effectively deliver genes to the Inhibition of hepatic fibrosis with artificial microRNA D Yang et al rodent liver has become common, 24 but it presents a risk for acute heart failure. 25 Recently, UTMD has been successfully used as a gene delivery tool in vivo experiments. [26] [27] [28] Microbubbles have been recognized as targeted carriers when combined with ultrasound for gene delivery. Many experimental UTMD studies have been performed by incubating gene vectors with microbubbles to coat their surface. The self-made microbubbles with a size range from 1 to 8 mm are long circulation ultrasound contrast agents, which consist of a lipid shell encapsulating perfluoropropane gas. 29 They have a significant role both in diagnosis and in therapy, which has been confirmed by numerous previous researches. [30] [31] [32] Unfortunately, the gas core and the thin shell of microbubbles limit its gene-carrying capacity. In contrast to microbubbles, the gene loading efficacy of liposomes has been confirmed, especially the cationic liposomes, which carry genes efficiently by binding negatively charged DNA to positively charged liposomes through electrostatic interaction. 33 DC-Chol is a charged lipid that gives the liposomes a positive charge that can efficiently combine with a negatively charged DNA plasmid. The ability of the biotinylated cationic liposomes to bind DNA was analysed using a gel retardation assay. When cationic liposomes and plasmid DNA volume ratio is greater than or equal to 6:1, no free DNA could be detected. This implies that all DNA is complexed with the liposomes. However, the fluid structure makes them no acoustic properties and can not be used to target tissue with ultrasound. Avidin-biotin interactions are strong and have been used successfully. 34 Therefore, we developed the novel cationic liposome-bearing microbubbles by mounting cationic liposomes on microbubbles shells through the biotin-avidin system to increase gene-loading capacity. We used those novel liposome-bearing microbubbles to deliver plasmid expressing amiCTGF into the liver tissue that was exposed to ultrasound. The novel cationic liposome-bearing coating did not alter the acoustic characteristics of the microbubbles. Furthermore, the results showed that the EmGFP signal appeared in the rat liver tissue as early as 24 h after transfection and was maintained for at least a week. Given these results, we delivered the plasmid into the rat liver tissue every 7 days to achieve stable expression of amiCTGF in vivo.
Dimethylnitrosamine (DMN)-induced liver fibrosis in rats is a valuable method to study early hepatic cirrhosis in humans and the corresponding pathological changes, including inflammatory cell infiltration, hepatocyte necrosis, distinctive fibrous septa and cirrhosis. 35 Hepatic fibrosis is the final pathological outcome for the majority of chronic liver injuries regardless of the aetiology, and it progresses to liver cirrhosis, which has high morbidity and mortality. If treated properly, hepatic fibrosis is a reversible process, avoiding the development of cirrhosis. 36, 37 In our study, short fibrotic septa extending into the liver lobules and some thin fibrotic septa between portal tracts were present 14 days after DMN administration. These findings are similar to observations by Li Ch et al. 38 Therefore, we chose to begin the therapy 14 days after DMN injection. Our study shows that repeated delivery of amiRNAs to treat hepatic fibrosis by UTMD is safe and convenient. In addition, our data demonstrate that the progression of hepatic fibrosis is effectively ameliorated, and cirrhosis is successfully prevented by downregulating CTGF expression through the delivery of amiCTGF by UTMD. However, the liver injury was not reversed after amiCTGF treatment, likely due to persistent DMN damage.
To investigate the role of amiCTGF in the treatment of hepatic fibrosis, we examined the expression of TGF-b1, a-SMA and type I collagen. It is generally accepted that CTGF is a downstream effector for TGF-b1. CTGF upregulation was positively correlated with the enhanced expression of TGF-b1 in fibrotic livers. 10, 11 Our present study found that silencing CTGF markedly reduced the upregulation of TGF-b1 expression. a-SMA is a marker of activated myofibroblasts. In the present study, CTGF inhibition downregulated a-SMA expression, indicating that amiCTGF can reduce HSC activation. Hepatic fibrosis is characterised by the accumulation of ECM, including type I collagen as the main component. Our study demonstrated that amiCTGF downregulated type I collagen expression and attenuated the development of hepatic fibrosis in rats.
In conclusion, the present study shows that the combination of novel liposome-bearing microbubbles and ultrasound is an effective way to deliver amiRNAs to the liver. We have successfully shown that amiCTGF delivered via microbubbles combined with ultrasound effectively silenced CTGF gene expression in the fibrotic liver tissue. Furthermore, amiCTGF significantly downregulated TGF-b1 expression, inhibited HSC activation, reduced the deposition of collagen and significantly regressed liver fibrogenesis. Our results suggest that gene silencing of CTGF using amiRNAs delivered via liposome-bearing microbubbles combined with ultrasound may be a valuable specific approach for the treatment of hepatic fibrosis.
MATERIALS AND METHODS

Plasmid DNA vector construction
Four different sequences targeting CTGF genes were designed using the BLOCK-iT RNAi Designer at http://rnaidesigner. invitrogen. com/rnaiexpress and verified using a BLAST search. The amiRNA and control scramble sequences (Table 1) were annealed and ligated into a pcDNA6.2-GW/ EmGFP-miR plasmid (Invitrogen, Carlsbad, CA, USA) that drives the expression of amiRNA with polymerase II, and contains a spectinomycin 
Preparation of biotinylated cationic liposomes and DNA-loading liposomes
Biotinylated cationic liposomes containing DPPC, PEG4000-positive lipids (DC-Chol) and DSPE-PEG2000-Biotin were mixed well with ultrapure water above the phase transition temperature of 60 1C. The suspension was divided into 1 ml aliquots in 3.5 ml vials and then lyophilised with a freeze drier overnight. Next, the freeze-dried powder was dissolved in 1 ml ultrapure water. The sealed vial was then oscillated for 60 s with a mechanical amalgamator (AT & M, Beijing, China) at a frequency of 6000. After sonication, the lipid suspension was washed three times with 10 mM phosphate-buffered saline (pH 7.4), followed by 5 min of centrifugation at 300 g. The suspension was then lyophilised again with the freeze drier. The freeze-dried biotinylated cationic liposomes were divided into 200 mg aliquots in 3.5 ml vials. Next, 1 ml of ultrapure water was added to the vial to completely dissolve the powder. Then, the biotinylated cationic liposome solution was extruded through 0.22-mm pore size filters, and the biotinylated cationic liposome solution was prepared. The samples were observed with a transmission electron microscope (Hitachi Inc, Tokyo, Japan).
A gel retardation assay was used to determine the volume ratio for the biotinylated cationic liposomes that exhibited complete complex formation with DNA. DNA (0.5 mg, 0.25 mg ml À 1 ) was complexed with the biotinylated cationic liposomes (5 mg ml À 1 ) at different volume ratios and incubated at room temperature for 20 min. Bromophenol blue was added to the samples. Next, the samples were electrophoresed in a 1% agarose gel containing ethidium bromide in a TAE buffer solution at 90 V for 40 min. The average particle size and the z potential of the liposomes and DNA-loading liposomes were measured by a Coulter particle counter (Omec Technology Co, Ltd, Zhuhai, China) and a Malvern zeta potential measuring instrument (Malvern instrument Co, Ltd, Malvern, England), respectively.
Preparation of biotinylated microbubbles
An appropriate amount of DPPG, DSPC and PEG-4000 supplemented with DSPE-PEG2000-Biotin was mixed well with ultrapure water in a 60 1C thermostatic water bath. The resulting suspension was dispersed into 2 ml vials (1 ml per vial) and then lyophilised with a freeze drier. The prepared powder from lyophilisation was dispersed in 1 ml of a solution containing 50% glucose, propylene glycol and glycerine with a volume ratio of 8:1:1. The air in the vial was substituted by perfluoropropane. The vial was closed tightly and oscillated with a mechanical shaker (AT & M) with a frequency of 4000 for 60 s. 29 
Conjugation of biotinylated cationic liposomes with biotinylated microbubbles via avidin
The biotinylated microbubbles were washed three times with phosphatebuffered saline at 300 g for 5 min. An excess of avidin was added to the washed microbubbles. Next, the microbubbles were vortexed shortly and incubated with gentle shaking for 30 min at room temperature. After incubation, the avidin-bound biotinylated microbubbles were washed with three times with phosphate-buffered saline for 5 min centrifugations at 300 g to remove the free avidin, and then resuspended in 10 ml of phosphate-buffered saline. The DNA-loading cationic liposomes were then added to this suspension at a ratio of 6:1 (v/v) and incubated for 30 min at room temperature with gentle shaking. The DNA-loading cationic liposomes-bearing microbubbles were washed three times to remove the free biotinylated cationic liposomes. The concentration and average particle size of the microbubbles carrying DNA-loading liposomes were measured by light microscopy (Leica, Wetzlar, Germany) and a Coulter particle counter (Omec Technology Co, Ltd), respectively. Subsequently, to test the ability of the DNA-loading liposomes to bind to the surface of the biotinylated microbubbles, the procedure is as described previously except for the DNA-loading liposomes-containing propidium iodide-labelled plasmid DNA. Then, the samples were observed with confocal laser scanning microscopy (Leica).
Acoustic response and delivery of DNA-loading cationic liposomebearing microbubbles in vivo 
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Twenty-five rats were used. The GE Vivid 7 Dimension (General Electric Co, Fairfield, CT, USA), a commercial clinical apparatus, was used at the operating second-harmonic mode (transmit 1.5 MHz/receive 3.2 MHz) with an S4 transducer. The parameters used were described previously. 22 The DNAloading cationic liposomes-bearing microbubbles were created as described above. The liver was located using two-dimensional echographic images. Next, the microbubbles were injected using a scan depth of 3.0 cm and a total of 0.5 ml kg À 1 of the DNA-loading cationic liposomes-bearing microbubbles with 0.2 mg kg À 1 plasmid were infused slowly via the caudal vein. The real time scanning mode was used with a low mechanical index (MI ¼ 0.08) to visualise the liver. The scanning mode was rapidly switched to FLASH mode (MI ¼ 1.0) to destroy the microbubbles. To allow for a wider field of delivery, the transducer was positioned transversely to the liver, and ultrasound was transmitted using a slow sweep along the length of the liver. All rats survived the experiment. The rats were randomly divided into four groups. The right liver lobes were collected after 24 h for six rats, 4 days for seven rats, 7 days for six rats and 10 days for six rats. The kidney, lung and spleen tissues were collected on day 4. The right liver lobes of six normal untreated-rats were collected as control under general anaesthesia and immediately frozen in liquid nitrogen. The frozen sections were prepared rapidly and then observed under a fluorescence microscope (Leica). Five fields were selected randomly from each of two sections. The fluorescence intensity of EmGFP was quantified using IMAGE-PRO PLUS software (Media Cybernetics Inc, Bethesda, MD, USA).
Animal models and protocol
The rats were randomly divided into four groups, including the normal control group (n ¼ 8), the dimethylnitrosamine (DMN, Sigma)-induced model group (n ¼ 8), the amiScramble group (n ¼ 8) and the amiCTGF group (n ¼ 8). In the normal control group, rats received intraperitoneal saline injections for 3 consecutive days per week for up to 4 weeks. In the DMN model, amiScramble and amiCTGF groups, rats received an intraperitoneal injection of 1% DMN (1 ml kg À 1 body weight) for 3 consecutive days per week for up to 4 weeks. At the end of the second and third weeks, the DMN model group received a slow bolus injection of 0.5 ml kg À 1 body weight of microbubbles, followed by 1 ml of saline to wash the tube via the caudal vein. Next, ultrasound was applied as described. At the end of the second and third weeks, the amiScramble and the amiCTGF groups were injected with 0.5 ml kg À 1 of cationic liposomesbearing microbubbles coupled with amiScramble plasmid or amiCTGF plasmid, respectively. Injections were followed by 1 ml of saline to wash the tube via the caudal vein, and ultrasound was applied as described.
All rats were euthanised 4 weeks after the DMN or saline administration under general anaesthesia. The liver tissue was quickly removed and a portion was instantly frozen in liquid nitrogen for western blot and realtime reverse transcriptase-PCR analyses. Another portion of the liver was fixed in 10% phosphate-buffered formalin for histopathological studies.
Histology and immunohistochemistry
All paraffin-embedded liver tissues were stained with haematoxylin and eosin for histopathological examination, and picrosirius red for collagen determination. Collagen densitometry was quantified using IMAGE-PRO PLUS software. Immunohistochemical examinations were completed to detect the expression of CTGF, TGF-b1 (Abcam, Cambridge, MA, USA), a-SMA and type I collagen (Boster, Wuhan, China) in the liver. The staining intensity of CTGF, TGF-b1, a-SMA and type I collagen was quantified using IMAGE-PRO PLUS software. Three fields were selected randomly from each of two sections, and eight rats from each group were examined.
Western blot analysis
Cells or liver tissue proteins were extracted using a Total Protein Extraction Kit (ProMab Biotechnology Inc, Richmond, CA, USA). The protein content was determined using the bicinchoninic acid method. The samples were mixed with 5 Â loading buffer. The lysates were boiled for 3 min and run through a 12% SDS-polyacrylamide gel at 300 mA for 70 min and then transferred to an immobilon polyvinylidene fluoride membrane. After blocking with 5% skim milk blocking buffer for 2 h at room temperature, the membranes were incubated with CTGF antibody, TGF-b1 primary antibody or GAPDH antibody (Santa Cruz, Santa Cruz, CA, USA) overnight at 4 1C. After washing, the membranes were hybridised with a horseradish peroxidase-conjugated secondary antibody at room temperature for 1 h and developed with an enhanced chemiluminescence detection kit (GE Healthcare Life Sciences, Pittsburgh, PA, USA). The protein signals were normalised to GAPDH levels. The housekeeping gene GAPDH was used as an internal control for standardisation in triplicate. The specificity of the amplification products was tested using a melting-curve analysis, and the comparative threshold (Ct) method was used to calculate the relative amount of mRNA of the treated sample to the control samples.
Statistical analysis
The results are presented as the mean and s.d. In the semiquantitative analysis, nonparametric test (Wilcoxon's test) was used; other statistical analysis of values was performed using the unpaired Student's t-test. All calculations were performed using SPSS 17.0 software (SPSS Inc, Chicago, IL, USA). Differences were considered to be highly significant at Po0.01.
